I agree @piggybanks, that gemcitabine +abraxane is a more contemporary treatment option with better OS outcomes than gemcitabine, so why then didn't OSL reference a paper looking at this chemo + radiotherapy then?
My point is, the 2011 reference chosen seems to conveniently inflate the improvement achieved in their open label trial because they've used a paper looking at the least aggressive approved chemotherapy treatment option. Their trial/s allow more then gemcitabine alone as chemotherapy, so these results at best, tell a skewed story.
I'm happy to agree to have different opinions.
Ann: Positive Overall Survival data released at ASCO 2019 Chicago, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.000(0.00%) |
Mkt cap ! $14.22M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | $1.00 | $16.29K | 16.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4283 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 1249 | 1 |
View Market Depth
| Last trade - 10.08am 25/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |